US pharma giant Pfizer will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...

The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF ...

Pfizer has a strong pipeline outside of vaccines. Padcev, Braftovi, Lorbrena and Elrexfio all target cancer treatments with strong growth profiles, including opportunities to become mega ...

highlight advancements across Pfizer’s industry-leading Oncology portfolio ASCO press program to feature overall survival and progression-free survival data for BRAFTOVI ® (encorafenib ...

Its oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer has ventured into the ...